Why the study?
Does targeted overexpression of PKCbeta2 isoform cause cardiomyopathy in mice, and does a PKCbeta-specific inhibitor improve the phenotype?
Does targeted overexpression of PKCbeta2 isoform cause cardiomyopathy in mice, and does a PKCbeta-specific inhibitor improve the phenotype?
Targeted overexpression of PKCbeta2 in the myocardium causes cardiomyopathy, which can be ameliorated by a specific inhibitor, highlighting a potential mechanism and therapeutic target for diabetic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
No clinical implications yet for PKCβ inhibitors; extends mechanistic evidence for PKCβ2 in cardiomyopathy models.
Increased cardiovascular mortality occurs in diabetic patients with or without coronary artery disease and is attributed to the presence of diabetic cardiomyopathy. One potential mechanism is hyperglycemia that has been reported to activate protein kinase C (PKC), preferentially the beta isoform, which has been associated with the development of micro- and macrovascular pathologies in diabetes mellitus. To establish that the activation of the PKCbeta isoform can cause cardiac dysfunctions, we have established lines of transgenic mice with the specific overexpression of PKCbeta2 isoform in the myocardium. These mice overexpressed the PKCbeta2 isoform transgene by 2- to 10-fold as measured by mRNA, and proteins exhibited left ventricular hypertrophy, cardiac myocyte necrosis, multifocal fibrosis, and decreased left ventricular performance without vascular lesions. The severity of the phenotypes exhibited gene dose-dependence. Up-regulation of mRNAs for fetal type myosin heavy chain, atrial natriuretic factor, c-fos, transforming growth factor, and collagens was also observed. Moreover, treatment with a PKCbeta-specific inhibitor resulted in functional and histological improvement. These findings have firmly established that the activation of the PKCbeta2 isoform can cause specific cardiac cellular and functional changes leading to cardiomyopathy of diabetic or nondiabetic etiology.
No takes yet. Share an insight, caveat, or question.
Wakasaki et al. (1997) studied Cardiomyopathy (n=24). LY333531 (PKC beta isoform-specific inhibitor) vs. Placebo (standard mouse chow) was evaluated on Left ventricular fractional shortening (%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: